Canaccord raised the firm’s price target on CervoMed to $65 from $50 and keeps a Buy rating on the shares. The firm told investors to buy the under-followed stock into its Q4 data in dementia with Lewy bodies as they expect the stock to continue to drift up meaningfully into the 4Q24 dataset.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
- CervoMed Shares Operational and Financial Insights Online
- CervoMed reports FY23 EPS (82c) vs ($11.20) last year
- CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
- Cervomed Inc. Braces for Impact: How Political Uncertainty and the Presidential Election Could Shake Up the Pharma Industry
- CervoMed’s Strategic $50 Million Private Placement Deal
